Experiments in glioblastoma [41] have shown that blocking canonical WNT signaling enhances CD4+/CD8+ immune cell infiltration in the TME, dramatically improving sensitivity to PD-1 therapy in gliomas while igniting ‘cold tumors’, suggesting that WNT3A may be a risk factor for immunotherapy. This evidence concerns the gene WNT3A and central nervous system cancer.